Point72 Asia (Singapore) Pte. Ltd. Kinnate Biopharma Inc. Transaction History

Point72 Asia (Singapore) Pte. Ltd.

  • $532 Billion
  • Q3 2024

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024
BUY
$2.24 - $2.66 $26,644 - $31,640
11,895 Added 540.68%
14,095 $37.5 Million
Q4 2023

Feb 14, 2024
BUY
$1.07 - $2.5 $2,354 - $5,500
2,200 New
2,200 $5.21 Million

Others Institutions Holding KNTE

# of Institutions
2
Shares Held
292K
Call Options Held
0
Put Options Held
0
View Full List

About Kinnate Biopharma Inc.

KNTE Quotes by TradingView
  • Ticker KNTE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 44,145,600
  • Description
  • Kinnate Biopharma Inc., a biopharmaceutical company, focuses on the discovery and development of small molecule kinase inhibitors to treat genomically defined cancers in the United States. The company develops KIN-2787, a rapidly accelerated fibrosarcoma inhibitor for the treatment of patients with lung cancer, melanoma, and other solid tumors; ...
More about KNTE
Track This Portfolio

Track Point72 Asia (Singapore) Pte. Ltd. Portfolio

Follow Point72 Asia (Singapore) Pte. Ltd. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Point72 Asia (Singapore) Pte. Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Point72 Asia (Singapore) Pte. Ltd. with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email